MX2017009119A - Composiciones y métodos para inhibir infecciones micóticas. - Google Patents

Composiciones y métodos para inhibir infecciones micóticas.

Info

Publication number
MX2017009119A
MX2017009119A MX2017009119A MX2017009119A MX2017009119A MX 2017009119 A MX2017009119 A MX 2017009119A MX 2017009119 A MX2017009119 A MX 2017009119A MX 2017009119 A MX2017009119 A MX 2017009119A MX 2017009119 A MX2017009119 A MX 2017009119A
Authority
MX
Mexico
Prior art keywords
fungus
methods
growth
compositions
inhibiting fungal
Prior art date
Application number
MX2017009119A
Other languages
English (en)
Inventor
Stefan Proniuk
ZUKIWSKI Alexander
Rappleye Chad
Original Assignee
Arno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arno Therapeutics Inc filed Critical Arno Therapeutics Inc
Publication of MX2017009119A publication Critical patent/MX2017009119A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan composiciones y métodos para inhibir el crecimiento micótico al administrar AR-12 a un hospedador infectado con un hongo tal como Hostoplasma capsulum, Aspergillus fumigatus y Trichophyton rubrum, Paecilomyces, Rhizopus, Fusarium, Scedosporium, Lomentospora, Apophysomyces, Coccidoides, Blstomyces, Candida que no es Candida albicans, y Pneumocytis.
MX2017009119A 2015-01-12 2016-01-07 Composiciones y métodos para inhibir infecciones micóticas. MX2017009119A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562102436P 2015-01-12 2015-01-12
US201562143777P 2015-04-06 2015-04-06
PCT/US2016/012514 WO2016114976A1 (en) 2015-01-12 2016-01-07 Compositions and methods for inhibiting fungal infections

Publications (1)

Publication Number Publication Date
MX2017009119A true MX2017009119A (es) 2018-03-16

Family

ID=56366735

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009119A MX2017009119A (es) 2015-01-12 2016-01-07 Composiciones y métodos para inhibir infecciones micóticas.

Country Status (10)

Country Link
US (1) US20160199351A1 (es)
EP (1) EP3244888A4 (es)
JP (1) JP2018502128A (es)
KR (1) KR20170102013A (es)
CN (1) CN107249584A (es)
AU (1) AU2016207029A1 (es)
CA (1) CA2973698A1 (es)
MX (1) MX2017009119A (es)
RU (1) RU2017128615A (es)
WO (1) WO2016114976A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029342B2 (en) 2012-09-17 2015-05-12 Board Of Regents Of The University Of Texas System Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
WO2017031075A1 (en) * 2015-08-17 2017-02-23 Arno Therapeutics, Inc. Methods and compositions for enhanced transungual delivery of ar-12
RS64770B1 (sr) 2016-03-07 2023-11-30 Agrofresh Inc Sinergistički postupci upotrebe jedinjenja benzoksaborola i gasova za prezerviranje kao antimikrobnih agenasa za useve
WO2018026811A2 (en) * 2016-08-01 2018-02-08 Ohio State Innovation Foundation Antifungal agents
WO2018144841A1 (en) * 2017-02-03 2018-08-09 Board Of Regents, The University Of Texas System Topical voriconazole for the treatment of pain
WO2020025683A1 (fr) * 2018-08-01 2020-02-06 Edix-O Sarl Compositions injectables a duree d'action prolongee pour leur utilisation dans le traitement de maladie de l'ongle et/ou pour accelerer la croissance de l'ongle
CN109966473B (zh) * 2019-05-14 2022-12-09 南京医科大学 一种还原型谷肽甘肽联合抗坏血酸和/或卡泊芬净的抗真菌产品及其应用
US11273124B2 (en) * 2019-05-23 2022-03-15 Brown University Antifungal nanoparticles for targeted treatment of fungal infections
WO2021054533A2 (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 산으로서 소르빈산을 포함하는 안정화된 에피나코나졸-함유 약학 조성물
KR20210032662A (ko) * 2019-09-17 2021-03-25 주식회사 바이오빌리프 킬레이트화제를 포함하는 안정화된 에피나코나졸-함유 약학 조성물
CN112322695A (zh) * 2020-11-03 2021-02-05 上海市肺科医院 一种ar-12对于mabc的体外抗菌活性的实验方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ522733A (en) * 2000-06-02 2004-05-28 Yu Liu Non-antibacterial tetracycline as anti-fungal agents
US20060079566A1 (en) * 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
US20060194769A1 (en) * 2005-01-25 2006-08-31 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
US8039502B2 (en) * 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
WO2009132342A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
CN102338100A (zh) * 2010-07-19 2012-02-01 鸿富锦精密工业（深圳）有限公司 风扇装置
AU2011201932A1 (en) * 2010-11-17 2012-05-31 University Of Rochester Treatment or prevention of fungal infections with PDK1 inhibitors
US20120027618A1 (en) * 2011-08-16 2012-02-02 General Electric Company Angled blade root

Also Published As

Publication number Publication date
WO2016114976A1 (en) 2016-07-21
US20160199351A1 (en) 2016-07-14
RU2017128615A (ru) 2019-02-14
EP3244888A1 (en) 2017-11-22
CN107249584A (zh) 2017-10-13
KR20170102013A (ko) 2017-09-06
JP2018502128A (ja) 2018-01-25
AU2016207029A1 (en) 2017-08-10
CA2973698A1 (en) 2016-07-21
EP3244888A4 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
MX2017009119A (es) Composiciones y métodos para inhibir infecciones micóticas.
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
MX359921B (es) Métodos de tratamiento tópico para infecciones microbianas.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MX2016001037A (es) Inhibidores de factores de transcripción y usos.
WO2014107740A3 (en) Methods for reducing cellular proliferation and treating certain diseases
WO2012119065A3 (en) Antifungal agents and uses thereof
EP4241844A3 (en) Compositions for topical treatment of microbial infections
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
CA2837341C (en) Method of determining vasoreactivity using inhaled nitric oxide
WO2012006516A3 (en) Protein kinase c activators and anticoagulant for the treatment of stroke
JP2012092110A5 (es)
IN2013MU01696A (es)
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX345467B (es) Metodo para inhibicion de actividad desubiquitinante.
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
MX2015013240A (es) Método para proporcionar neuroprotección ocular.
MX2017014912A (es) Compuesto para la profilaxis o el tratamiento de daño al organo.
MX2016010699A (es) Composiciones y metodos para tratar neutropenia.
MX2015001488A (es) Tratamiento de la inflamacion utilizando serelaxina.